Fierce Biotech
Pfizer adds to Seagen scrap heap with another early cancer candidate cull
About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, the company has trimmed another branch. Pfizer has scrapped a phase 1 antibody-drug conjugate that was being tested in solid tumors, a company spokesperson confirmed to Fierce Biotech.